肝脏 ›› 2025, Vol. 30 ›› Issue (11): 1466-1468.

• 前沿、探索与争鸣 • 上一篇    下一篇

5-羟甲基胞嘧啶在HBV相关肝癌高危人群中的评估价值

高国峰, 余姣   

  1. 201805 上海 解放军海军军医大学上海东方肝胆外科医院感染科
  • 收稿日期:2024-11-12 出版日期:2025-11-30 发布日期:2026-02-09
  • 通讯作者: 余姣,Email:yujiao7828@sina.com

The value of 5-hydroxymethylcytosine in predicting hepatocellular carcinoma risk in HBV-carrying population: an evaluation based on differential analysis

GAO Guo-feng, YU Jiao   

  1. Department of Infection, Shanghai Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai 201805, China
  • Received:2024-11-12 Online:2025-11-30 Published:2026-02-09
  • Contact: YU Jiao,Email:yujiao7828@sina.com

摘要: 目的 探讨5-羟甲基胞嘧啶(5hmC)评估慢性乙型肝炎(CHB)进展为肝细胞癌(HCC)的应用价值。方法 纳入CHB患者84例,HCC患者96例。其中2/3样本用于训练集,1/3样本用于验证集。采用改进的nano-hmC-Seal技术检测两组患者的5hmC水平。qPCR检测5hmC相关基因TET2、TET3表达水平,Pearson相关性分析TET3与5hmC的相关性。以受试者工作特征曲线下面积(AUC)评估基于TET3的5hmC预测模型对HCC早期诊断的应用价值。结果 HCC组5hmC水平较CHB组有所降低(训练集:0.73±0.31比0.98±0.31,验证集:1.01±0.34比2.98±1.25)。5hmC在转录启动点和转录端位点之间的区域显著丰富,并在侧翼区域耗尽。5hmC相关基因TET2以及TET3表达在HCC患者中显著下调,训练集:TET2 0.72±0.26比1.04±0.36,TET3 0.73±0.34比0.96±0.34;验证集:TET2 1.89±0.28比3.25±1.25,TET3 0.71±0.22比1.04±0.27。在训练集和验证集中,TET3表达与5hmC水平呈正相关。5hmC模型可用于预测CHB进展为HCC,训练集:AUC=0.81,95%CI:0.729~0.893;验证集:AUC=0.84, 95%CI:0.739~0.936。结论 基于5hmC测序的TET3表达是评估CHB患者进展为HCC的标志性分子。

关键词: 乙型肝炎病毒, 慢性乙肝, 肝细胞癌, 5hmC修饰

Abstract: Objective To clarify the application value of 5-hydroxymethylcytosine (5hmC) in evaluating the progression risk of chronic hepatitis B (CHB) to hepatocellular carcinoma (HCC) based on differential analysis. Methods Eighty-four CHB patients without HCC progression were included in the control group (CG), and 96 CHB patients with HCC development were included in the research group (RG). Two-thirds of the samples were used in the training set and one-third of the samples were used in the validation set to detect the level of 5hmC in both groups based on a modified nano-hmC-Seal technique. The expression levels of 5hmC-related genes TET2 and TET3 were quantified by qPCR method, and the correlation between TET3 and 5hmC was analyzed by Pearson′s correlation coefficients method. Receiver operating characteristic (ROC) curves were drawn to evaluate the application value of the TET3-based 5hmC prediction model in the early diagnosis of HCC. Results The expression of 5hmC in patients of RG group was lower than that in CG group, no matter in the training set or in the validation set (training set: 0.73±0.31 vs.0.98±0.31, validation set: 1.01±0.34 vs.2.98±1.25). 5hmC was significantly enriched in the region between the transcription initiation site and the transcription ending site but was depleted in the flanking region. 5hmC-related genes TET2 and TET3 were significantly down-regulated in HCC patients, both in the training set and in the validation set (training set: TET2 0.72±0.26 vs.1.04±0.36, TET3 0.73±0.34 vs.0.96±0.34, validation set: TET2 1.89±0.28 vs.3.25±1.25, TET3 0.71±0.22 vs.1.04±0.27). In both the training and validation sets, TET3 showed a positive association with 5hmC. ROC analysis results showed that the 5hmC prediction model could be used to predict the progression of CHB to HCC (training set: AUC=0.81, 0.729~0.893; validation set: AUC=0.84, 0.739~0.936). Conclusion TET3 expression based on 5hmC sequencing is a landmark molecule for evaluating the progression of HCC in CHB patients, which is worthy of further study and promotion.

Key words: Hepatitis B virus, Chronic hepatitis B, Hepatocellular carcinoma, 5hmC modification